Phage Display Platform-Tekbiotech-Yeast Display Service,Phage display technology

目录&服务

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Phage Display Platform

TekBiotech is committed to providing customers with high-affinity and high-specificity antibody drug early discovery technology services, and providing strong support for customers' subsequent CAR-T/CAR-NK lead sequence design, antibody humanization, drug target antibody development, antibody-drug conjugate (ADC) development, bispecific antibody development, and efficient blocking neutralizing antibody development and other downstream R&D work. TekBiotech has 10 years of project development experience and experience in drug antibody discovery, and can provide customers with high-quality camel-derived VHH discovery services for targets including but not limited to proteins, peptides, small molecules, viruses, membrane proteins, and mRNA, as well as scFv discovery services for different species (rabbit, mouse, sheep, camel, etc.).

Phage display technology (Phagepro Tech^®) is a biotechnology that inserts the DNA sequence of exogenous proteins or peptides into the appropriate position of the phage coat protein structural gene, usually the P3 protein of the M13 phage, so that the exogenous gene is displayed on the phage surface along with the expression of the coat protein. Based on phage display technology (Phagepro Tech^®), TekBiotech can provide customers with high-quality single-chain antibody phage display services including but not limited to VHH, scFv, etc. The capacity of the immune library is 10^9-10^10 (the capacity of the natural library is 10^10-10^12), the library diversity is >90%, the insertion rate is 95%, the positive rate is >95%, and other technical indicators meet the special requirements of different types of customers for antibody phage display libraries. The advantage of phage display is that it displays the diversity of variant antibody genes in the nanoantibody library. Each recombinant phage (the commonly used phage is M13 phage) displays different antigen binding domains on its surface. Compared with the traditional hybridoma method, phage display technology has a very outstanding efficiency advantage in antibody gene display and screening (for example, the hybridoma fusion efficiency is generally<0.4%, that is, there are about 4 fusions in 1000 fusion cells; while phage display can easily obtain 10^8-10^9 correct antibody sequences). At the same time, TekBiotech can also provide one-stop technical services such as downstream antibody in vitro validation (including but not limited to affinity validation, antibody blocking validation, cross-reaction validation and other drugability evaluation and validation experiments) for antibody phage display, antibody humanization, antibody affinity maturation, CAR-T/CAR-NK lead sequence design and cell killing validation. Customers only need to provide specific experimental requirements and target information. TekBiotech scientists can design reasonable solutions and customize them according to customer needs to help customers' scientific research projects and drug antibody development.

█ Antibody Development Service Based On Phage Display Technology

Based on phage display technology platform technology, TekBiotech can provide customers with camel-derived VHH nanoantibody library, scFv antibody, Fab antibody and other antibody display library construction and screening services from different species. Among them, the VHH nanoantibody library, also known as the camel-derived heavy chain antibody library, has an antibody molecular weight of 15kDa and is a unique antibody produced by camel-derived animals. It is currently widely used in the development of CAR-T/CAR-NK therapeutic antibodies. scFv and Fab antibodies can come from PBMC cells of hosts such as mice, rats, sheep, rabbits, and humans. From antigen preparation to antibody activity verification, the phage display discovery path is shown in Figure 1:

Phage display technology platform-tekbiotech1.png

Figure 1 General process of antibody discovery based on phage technology platform

█ Types of Phage Display Technology Antibody Development Services

Tekbiotech provides customers with antibody discovery services based on the M13 phage display system, as shown in Figure 2 or Table 1:

Table 1 Antibody discovery types based on phage display technology

Antibody Form	Species Source	Phage Type	Antibody Encapsulation
scFv Antibody Form	Human	M13	TG1 library/phage particle library
	Mouse
	Rabbit
	Sheep
Fab Form Antibody	Human
	Mouse
	Rabbit
VHH Nanoantibody	Alpaca
VHH Nanoantibody	Camel

Phage display technology platform-tekbiotech2.png

Figure 2 Antibody discovery types based on phage display technology

█ Phage Technology Platform Service Advantages

Phage display technology platform-tekbiotech3.png

Phage display technology platform-tekbiotech4.png

Phage display technology platform-tekbiotech5.png

Phage display technology platform-tekbiotech6.png

Phage display technology platform-tekbiotech7.png

Wide adaptability to species:

Monoclonal antibody development

of human, mouse, rabbit, sheep,

alpaca, camel, fish and other

species is compatible

Short development cycle: After

obtaining PBMC, it takes 4-6

weeks from library construction

to screening to obtain antibody

sequences

Multiple target antibody discovery

services are available: protein,

peptide, small molecule, virus,

membrane protein, mRNA, etc.

Large library capacity: immune

library capacity 10^9-10^10,

natural library capacity 10^10

-10^12

Flexible library screening methods:

solid phase screening, liquid

phase screening, cell screening,

magnetic bead screening, etc.

Phage Display Technology

Based on phage display technology, Tek Biotech can provide customers with high-quality single chain antibody phage display services including but not limited to VHH, scFv, etc. The phage library capacity can reach 10 ^ 8-10 ^ 9, and the library diversity, insertion rate, and positivity rate can all reach over 90%, meeting the quality requirements of various customers for antibody phage display libraries.

If you need more technical information, please send an email to info@tekbiotech.com

Phage Display Platform Frequently Asked Questions

What is Phage Display Technology?

Phage Display is a technology for screening and characterizing the interaction of target molecules (e.g. antibodies, peptides, proteins, etc.) with specific targets by displaying exogenous proteins or peptides on the surface of phages. It utilizes phage as a carrier to display diverse protein libraries on the surface of phage. By binding protein or peptide sequences with specific affinity to the target, high-affinity molecules can be screened. Phage display technology is widely used in the fields of antibody development, drug screening, vaccine design and molecular recognition, and is an important tool in biopharmaceutical and basic research.
How does phage display technology perform antibody screening?

In phage display technology, antibody screening is usually performed by constructing a diverse library of antibodies and screening them by binding to target antigens. First, the antibody gene is cloned into the genome of the phage so that the heavy or light chain of the antibody binds to the shell protein on the surface of the phage (usually pIII or pVIII protein) to form an antigen-antibody complex. Next, a solid surface containing the target antigen (e.g., a microtiter plate or magnetic beads) is bound to the antibody-displayed phage. By eluting the unbound phage, the remaining phage are reproduced and amplified by lysis. Through multiple rounds of screening, antibodies with high affinity and specificity can be selected from them.
What are the advantages of phage display technology?

The main advantages of phage display technology include its efficiency, flexibility, low cost and high throughput. Phage display allows efficient screening without the need for purification of target molecules and cumbersome experiments, and is able to obtain molecules with high affinity and specificity through multiple rounds of screening. In addition, phage display technology can construct large and diverse libraries in a short period of time, which makes the screening process highly flexible and versatile. In addition, phage display technology is easy to operate, low cost, and can be widely used in antibody screening, peptide library screening, vaccine development and other fields.
What are the application areas of phage display technology?

Phage display technology is widely used in many fields such as antibody discovery, drug screening, vaccine development, targeted therapy, molecular recognition and biomarker discovery. In antibody discovery, phage display technology can help researchers screen monoclonal antibodies with high affinity to the target; in drug screening, phage display technology can effectively screen small molecules with anti-cancer, anti-virus, anti-bacteria, etc.; in vaccine development, phage display technology can be used for the design and screening of candidate antigens and the development of efficient vaccines. In molecular recognition and biomarker discovery, phage display technology can be used to screen peptides or proteins that are highly specific to specific cell surface markers.
How to improve the screening efficiency of phage display technology?

Improving the screening efficiency of phage display technology is mainly achieved by optimizing the screening conditions, increasing the diversity of libraries and implementing high-throughput screening. Optimization of screening conditions includes the use of appropriate buffers, temperatures and pH values to ensure that phages are able to bind effectively to target molecules. Increasing library diversity is essential to ensure that the screening yields high-affinity molecules, and the greater the library diversity, the higher the reliability of the screening results. High-throughput screening techniques (e.g., flow sorting) can effectively accelerate the screening process, shorten the screening time and improve the accuracy.

What is Phage Display Technology?

Phage Display is a technology for screening and characterizing the interaction of target molecules (e.g. antibodies, peptides, proteins, etc.) with specific targets by displaying exogenous proteins or peptides on the surface of phages. It utilizes phage as a carrier to display diverse protein libraries on the surface of phage. By binding protein or peptide sequences with specific affinity to the target, high-affinity molecules can be screened. Phage display technology is widely used in the fields of antibody development, drug screening, vaccine design and molecular recognition, and is an important tool in biopharmaceutical and basic research.
How does phage display technology perform antibody screening?

In phage display technology, antibody screening is usually performed by constructing a diverse library of antibodies and screening them by binding to target antigens. First, the antibody gene is cloned into the genome of the phage so that the heavy or light chain of the antibody binds to the shell protein on the surface of the phage (usually pIII or pVIII protein) to form an antigen-antibody complex. Next, a solid surface containing the target antigen (e.g., a microtiter plate or magnetic beads) is bound to the antibody-displayed phage. By eluting the unbound phage, the remaining phage are reproduced and amplified by lysis. Through multiple rounds of screening, antibodies with high affinity and specificity can be selected from them.
What are the advantages of phage display technology?

The main advantages of phage display technology include its efficiency, flexibility, low cost and high throughput. Phage display allows efficient screening without the need for purification of target molecules and cumbersome experiments, and is able to obtain molecules with high affinity and specificity through multiple rounds of screening. In addition, phage display technology can construct large and diverse libraries in a short period of time, which makes the screening process highly flexible and versatile. In addition, phage display technology is easy to operate, low cost, and can be widely used in antibody screening, peptide library screening, vaccine development and other fields.
What are the application areas of phage display technology?

Phage display technology is widely used in many fields such as antibody discovery, drug screening, vaccine development, targeted therapy, molecular recognition and biomarker discovery. In antibody discovery, phage display technology can help researchers screen monoclonal antibodies with high affinity to the target; in drug screening, phage display technology can effectively screen small molecules with anti-cancer, anti-virus, anti-bacteria, etc.; in vaccine development, phage display technology can be used for the design and screening of candidate antigens and the development of efficient vaccines. In molecular recognition and biomarker discovery, phage display technology can be used to screen peptides or proteins that are highly specific to specific cell surface markers.
How to improve the screening efficiency of phage display technology?

Improving the screening efficiency of phage display technology is mainly achieved by optimizing the screening conditions, increasing the diversity of libraries and implementing high-throughput screening. Optimization of screening conditions includes the use of appropriate buffers, temperatures and pH values to ensure that phages are able to bind effectively to target molecules. Increasing library diversity is essential to ensure that the screening yields high-affinity molecules, and the greater the library diversity, the higher the reliability of the screening results. High-throughput screening techniques (e.g., flow sorting) can effectively accelerate the screening process, shorten the screening time and improve the accuracy.

Consult Now Phage Display Platform